TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02689141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v.
Study: NCT01116154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03668912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided participation discharge programme
Description: A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
Study: NCT01804465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SipT Treatment
Description: All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SipT Treatment
Description: All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
Study: NCT00524784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ApoCell
Description: Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
Study: NCT03081260

Intervention type: OTHER
Group type: OTHER
Intervention: Patellar resurfacing
Description: The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.

Intervention type: OTHER
Group type: OTHER
Intervention: Patellar non-resurfacing
Description: Non-resurfacing of the patella does not involve any additional surgical action
Study: NCT02152033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Continuing Care
Description: All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as Usual
Description: Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
Study: NCT03928600

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cervical Foley combined with Misoprostol
Description: Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
Study: NCT01922440

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study: NCT03928600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dinoprostone 10mg insert OR
Description: Application for 24h of Dinoprostone 10mg insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Application of vaginal misoprostol 25ug 4/4h until 150ug
Study: NCT03926169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
Study: NCT03926169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for risankizumab
Description: Placebo for risankizumab is administered as a SC injection in PFS
Study: NCT02251652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate
Description: Ingenol mebutate 0.05% gel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: 1-2 sprays, 5 seconds each, with a 5 second interval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: 1-2 sprays, 5 seconds each, with a 5 second interval
Study: NCT03253497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorobenzene Liquid
Description: before induction will be used for oropharynx
Study: NCT03328312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Time period from administration of the reversal agent to recovery of TOFR \>0.9

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: neostigmine+atropine
Description: Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neostigmine+atropine+sugammadex
Description: 4. Time of extubation
Study: NCT00828347

Intervention type: DRUG
Group type: OTHER
Intervention: 1.0 μg/day Alfacalcidol
Description: We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: 0.25 μg/day Alfacalcidol
Description: We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
Study: NCT02490228

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TAURFUC
Description: female patients with urethral caruncle will receive transurethral resection combine with extension tube.
Study: NCT02959931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Potassium Meal
Description: Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Potassium Meal
Description: Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
Study: NCT03918083

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wellness
Description: Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
Study: NCT02853110

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypo-FLAME study
Description: SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
Study: NCT05373368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi purpose activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi purpose activities
Study: NCT02420431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation (treatment as usual)
Description: Stress management, relaxation training, exercise and dietary advice.
Study: NCT05055011

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT04299503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crisaborole Topical Ointment
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Ointment
Description: For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
Study: NCT01257997

Intervention type: BIOLOGICAL
Intervention: 15N-Thymidine, 2H-Water
Description: Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).
Study: NCT02387060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-Bupivacaine
Description: Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H-Bupivacaine
Description: Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intrathecal administration of fentanyl 25 mcg
Study: NCT01716767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol
Description: The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
Study: NCT00748618

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard vitamin D3 treatment
Description: 10,000 I.U./wk of vitamin D3 orally for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose vitamin D3 treatment
Description: 50,000 I.U./wk of vitamin D3 orally for 6 months
Study: NCT01826539

Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap includes a donor nerve
Description: the donor nerve is attached with the flap for sensory reconstruction of the finger
Study: NCT03946774

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein shake
Description: It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein shake
Description: It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate.
Study: NCT04042909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counter Attitudinal Advocacy
Description: same as Counter Attitudinal Advocacy arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Normative Feedback
Description: same as Personalized Normative Feedback arm
Study: NCT03066323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice with tea extract
Description: Rice with tea extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice without tea extract
Description: Rice without tea extract
Study: NCT01780246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study: NCT03850093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin1200 mg
Description: patients received 1200mg gabapentin 2 hrs preoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol 2.5mg
Description: patients received 2.5mg bisoprolol 2 hrs preoperative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received oral placebo 2 hrs preoperative
Study: NCT04798352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: 6-minute walk test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: 6-minute walk test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WIQ functional questionnaire
Description: WIQ functional questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WIQ functional questionnaire
Description: WIQ functional questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaires (EQ5D5L and SF-36)
Description: quality of life questionnaires (EQ5D5L and SF-36)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaires (EQ5D5L and SF-36)
Description: quality of life questionnaires (EQ5D5L and SF-36)
Study: NCT02594930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: synovial biopsy of total knee arthroplasty
Description: synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
Study: NCT02697240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous citrulline
Description: Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
Study: NCT03766412

Intervention type: OTHER
Intervention: High School start time
Description: The time that the school starts

Intervention type: OTHER
Intervention: High School start time
Description: The time that the school starts
Study: NCT01210612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral CAI
Description: five-toed socks usage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral CAI
Description: five-toed socks usage
Study: NCT00405808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Once daily in the morning
Study: NCT01716767

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
Study: NCT00405808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily in the morning
Study: NCT01956305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-7309
Description: DS-7309 powder in bottle
Study: NCT00560859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenotonsillectomy (AT) - removal of adenoids and tonsils
Description: Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils

Intervention type: OTHER
Group type: OTHER
Intervention: Watchful Waiting
Description: Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
Study: NCT01956305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match DS-7309 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg tablet for Cohort F
Study: NCT00753857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Facts Box
Description: Educational intervention of 1 page summary of drug efficacy and side effects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Brief Summary
Description: Ads consisted of the standard second page called the brief summary
Study: NCT00080873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02304133

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study: NCT01691781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Each subject will receive one week of lisinopril and return for repeat for blood measurements.
Study: NCT00996645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksheet to facilitate goal-setting and action plans
Description: Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
Study: NCT01082991

Intervention type: OTHER
Group type: OTHER
Intervention: Preemptive Rapid Response Team intervention
Description: Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
Study: NCT04110301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62 Injection
Description: 1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction